Screener
Avalo Therapeutics AVTX Business Segments — Clinical expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept avtx:ClinicalExpenses.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Nonclinical expenses | $249 | $179 | $640 | $262 |
| Clinical expenses | 3,712 | 7,215 | 9,344 | 11,065 |
| CMC expenses | 5,068 | 3,266 | 9,194 | 5,245 |
| License and milestone expenses | 10,000 | — | 10,000 | — |
| Internal expenses: | ||||
| Salaries, benefits and related costs | 2,630 | 2,181 | 5,216 | 4,030 |
| Stock-based compensation expense | 1,680 | 1,116 | 2,923 | 2,418 |
| Other | 79 | 117 | 149 | 175 |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's business segments — clinical expenses?
- Avalo Therapeutics (AVTX) reported business segments — clinical expenses of $3.71M in Q2 2026.
- How has Avalo Therapeutics's business segments — clinical expenses changed year-over-year?
- Avalo Therapeutics's business segments — clinical expenses decreased by 48.6% year-over-year, from $7.22M to $3.71M.
- What is the long-term trend for Avalo Therapeutics's business segments — clinical expenses?
- Over 2 years (2023 to 2025), Avalo Therapeutics's business segments — clinical expenses has grown at a 107.4% compound annual growth rate (CAGR), from $5.78M to $24.87M.
- What does business segments — clinical expenses mean?
- Includes all costs directly related to conducting human clinical trials, such as patient recruitment, site management, and data collection. These expenses reflect the intensity and scale of the company's efforts to validate drug candidates in human subjects. High clinical expenses are indicative of active, late-stage development programs moving toward potential regulatory submission.
Ask your AI about Avalo Therapeutics's business segments — clinical expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude